Search results
Results from the WOW.Com Content Network
A depot injection, also known as a long-acting injectable (LAI), is a term for an injection formulation of a medication which releases slowly over time to permit less frequent administration of a medication.
Lupron injection was approved by the FDA for treatment of advanced prostate cancer on 9 April 1985. [45] [4] [43] [44] Lupron depot for monthly intramuscular injection was approved by the FDA for palliative treatment of advanced prostate cancer on 26 January 1989. [8]
Template:Medications and dosages used in hormone therapy for transgender men References ^ Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG (November 2017).
[38] [39] It is given by intramuscular or subcutaneous injection and forms a long-lasting depot, from which it is slowly released over a period of several months. It takes one week to take effect if given after the first five days of the period cycle, and is effective immediately if given during the first five days of the period cycle.
Depot MPA (DMPA) and EC/MPA were developed by Upjohn in the 1960s. [ 12 ] [ 13 ] DMPA (brand name Depo-Provera) was introduced for use as a progestogen-only injectable contraceptive for the first time outside of the United States in 1969 and was subsequently approved for use in birth control in the United States in 1992.
Agovirin Depot: Aqueous suspension: 50–100 mg 1x/1–2 weeks Testosterone phenylacetate b: Perandren, Androject: Oil solution: 50–200 mg 1×/3–5 weeks Mixed testosterone esters: Sustanon 100, Sustanon 250: Oil solution: 50–250 mg 1×/2–4 weeks Testosterone undecanoate: Aveed, Nebido: Oil solution: 750–1,000 mg 1×/10–14 weeks ...
Estrogen levels after a single intramuscular injection of 10 mg estradiol valerate in oil in 24 postmenopausal women. [9] Determinations were made for both Progynon Depot 10 and Estradiol Depot 10, for a total of 48 measurements per point. [9] Assays were performed using GC/MS-NCI/SIM. [9] Source was Schug et al. (2012). [9]
In 2023 an open source autoinjector was developed that could be digitally replicated with a low cost desktop 3D printer. [4] It was tested against the then current standard (ISO 11608–1:2022) [ 5 ] for needle-based injection systems and found to cost less than mass manufactured systems.